Dr. Friderike Bruchmann is Co-Founder and CEO of XO Life, a Munich-based digital health company building the ImpactMonitor meta-platform that connects patients, healthcare experts, and pharmaceutical companies for trusted therapy support.

Friderike earned her PhD at TUM School of Management, where she researched entrepreneurial networks, angel and VC investments, and venture performance, and previously held roles at Siemens, Deutsche Bank, and Telekom Innovation Laboratories.

A serial entrepreneur, Friderike also co-founded Medikura, a drug communication platform for patients and pharma, demonstrating a consistent mission to transform patient-pharmaceutical engagement through technology.

Under her leadership, XO Life has raised over $14M in total funding, secured Series A backing from Sandwater and Grazia Equity, and expanded its platform to serve more than 40 pharmaceutical companies including three of the top ten global players.

XO Life's Brite platform supports patients across medications, therapies, and indications, with a multinational team of 13-plus nationalities and active plans for European and global expansion.